Position · Core / Quality Compounders
Estée Lauder Companies (EL)
Compare vs. competitors: Estée Lauder vs. Coty →
Read the full fiscal Q3 2026 earnings report →
Subscribe to EL updates (RSS) →
Download full 3-statement model (.xlsx) →
Thesis StatementA margin-recovery story in prestige beauty, diversifying the book away from every AI-infrastructure name, on real, improving profitability rather than a re-rating narrative.
Core Thesis
Estée Lauder is a global prestige beauty leader across skin care, makeup, fragrance, and hair care, operating in over 150 countries with a well-known multi-brand portfolio including Estée Lauder, Clinique, M.A.C, and La Mer — a durable brand moat, currently...
Financial Metrics
- Market Cap$30B
- P/E (TTM)N/A — unprofitable on a trailing basis
- EPS (TTM)−$0.70
- Div. Yield1.70%
- Price$83.71
Bear Case
Prestige beauty demand in China and travel retail stays soft longer than expected, restructuring costs run higher than planned, and the company stays unprofitable for longer, testing the dividend it currently still pays.
Investment Thesis
- The Thesis
- Estée Lauder is a global prestige beauty leader across skin care, makeup, fragrance, and hair care, operating in over 150 countries with a well-known multi-brand portfolio including Estée Lauder, Clinique, M.A.C, and La Mer — a durable brand moat, currently obscured by a genuine cost-cutting restructuring.
- The Catalyst
- Progress on the company's ongoing restructuring program and any stabilization in China and travel-retail demand would be the concrete signs the turnaround is working, rather than continued margin pressure.
- The Risk
- Prestige beauty demand in China and travel retail could stay soft longer than expected and restructuring costs could run higher than planned, leaving the company unprofitable for longer and testing the dividend it currently still pays.
- The Connection
- This is my one deliberate non-tech, non-AI holding — a real diversifier against the thematic clustering the rest of the book leans into, chosen precisely because it has nothing to do with AI infrastructure or semiconductors.
Pre-Mortem Thesis Invalidation Parameters
Codified in advance, before any of these have happened, so a future decision to hold or exit isn't rationalized in the moment. If a condition below is met, the thesis as written is invalidated and the position gets re-underwritten from scratch — not automatically sold, but automatically questioned.
| Metric / Event | Automatic Review Trigger |
|---|---|
| China / Travel Retail Organic Sales | Stays negative for 3 consecutive quarters. |
| Dividend Coverage | The company cuts or suspends the dividend. |
The Ordinary has visibly helped my own skin
I use The Ordinary, the skincare brand under Estée Lauder's Deciem subsidiary, and it has made a real, noticeable difference for my skin and acne. That's a genuinely different experience of the company than the household-name prestige brands (Estée Lauder, Clinique, La Mer) that get most of the attention in coverage of this stock — The Ordinary built its reputation on effective, ingredient-transparent, affordably priced products, which is a distinct value proposition inside a portfolio that's otherwise about prestige pricing power.
One person's skincare results aren't clinical data, and my own experience doesn't tell me anything about the restructuring or the China/travel-retail softness that's actually driving the bear case. But it's a real, first-hand data point that at least one brand in the portfolio is delivering a product people actually want to keep buying, at a moment when the company's broader turnaround is still unproven.
| Market cap | $30B |
|---|---|
| P/E ratio (TTM) | N/A — unprofitable on a trailing basis |
| EPS (TTM) | −$0.70 |
| Dividend yield | 1.70% |
| Shares outstanding | 247.3M |
| Sector | Perfumes, cosmetics & toiletries |
| EBITDAEarnings Before Interest, Taxes, Depreciation, and Amortization — a measure of operating profitability before financing and accounting decisions. EV/EBITDA compares a company's full value (including debt) to this figure, often used to compare companies with different capital structures. | EV/EBITDA 24.51x (5yr EBITDA growth −35.2%) |
| PEG ratioPrice/Earnings-to-Growth: the P/E ratio divided by expected earnings growth. Below 1.0 is often read as cheap relative to growth; above suggests the market is pricing in a lot of future growth already. Different providers use different growth-rate assumptions, so figures vary by source. | N/A (negative growth) |
| Capex | Not cleanly disclosed for FY26 as of this writing |
Valuation Logic
Trailing earnings are still thin enough that P/E isn't a clean anchor; the valuation case rests on the raised forward EPS guide ($2.35–2.45) actually being delivered as the restructuring matures.
About the business
Estée Lauder is a global prestige beauty leader across skin care, makeup, fragrance, and hair care, with brands including Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, and others. It operates in over 150 countries, sold through department stores, travel retail, specialty stores, and e-commerce.
Why I own it
This is my one deliberate non-tech, non-AI holding — a real diversifier against the thematic clustering the rest of the book leans into. It's a well-known brand portfolio going through a genuine restructuring (currently unprofitable on a trailing basis), which is exactly why it's kept at a modest size: I want the diversification without betting heavily on a turnaround I can't fully evaluate yet.
Risk/Reward Profile
| Bull Case | Bear Case |
|---|---|
| Estée Lauder's restructuring program cuts costs enough to restore GAAP profitability, its travel-retail and Asia-Pacific businesses recover from recent softness, and the prestige-beauty category keeps growing globally. | Prestige beauty demand in China and travel retail stays soft longer than expected, restructuring costs run higher than planned, and the company stays unprofitable for longer, testing the dividend it currently still pays. |
Download this position's data
Fundamentals, scenario matrix, and risk/reward table — exported exactly as published on this page, no reformatting.